AshHill et al. invest in Heart Metabolics

The company will use the funding to advance US clinical development of perhexiline, its lead drug candidate for the treatment of heart failure symptoms in patients with hypertrophic cardiomyopathy (HCM).

Recent well-known cases of HCM include footballer Fabrice Muamba and Norwegian swimmer Alexander Dale Oen.

Company
Heart Metabolics is based in London and was founded by Professor Michael Frenneaux and Dr Houman Ashrafian after finding that abnormal cardiac energetics and the heart failure symptoms of HCM could be reversed by treatment with the known drug perhexiline.

In June 2012 the company obtained orphan designation from the FDA for the use of perhexiline as first-line treatment for moderate-to-severe heart failure due to HCM. The company has also in-licensed a new chemical entity drug candidate from the University of Adelaide for the treatment of heart failure.

People
Steven R Smith of AshHill, as well as Andrew O'Brien and Michael Bettess of TTCF, joined Heart Metabolics' board of directors. Peter G Milner was appointed CEO of the company and will be based in the US.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Healthcare
• Early-stage
• United Kingdom
• United States